{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:18:17Z","timestamp":1770844697681,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2021.770419","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:21:05Z","timestamp":1632990065000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Editorial: Key Players in Systemic Sclerosis: The Immune System and Beyond"],"prefix":"10.3389","volume":"12","author":[{"given":"Philippe","family":"Guilpain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic Sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.10.010","article-title":"Systemic Sclerosis: Recent Insights","volume":"82","author":"Elhai","year":"2015","journal-title":"Joint Bone Spine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219748","article-title":"Tgf\u03b2 Promotes Low IL10-Producing ILC2 With Profibrotic Ability Involved in Skin Fibrosis in Systemic Sclerosis","author":"Laurent","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208213","article-title":"Treatment With Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis","volume":"75","author":"Ponsoye","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","article-title":"T-Cell Costimulation Blockade Is Effective in Experimental Digestive and Lung Tissue Fibrosis","volume":"20","author":"Boleto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of Patients With Systemic Sclerosis-Associated Polyarthritis and Myopathy Treated With Tocilizumab or Abatacept: A EUSTAR Observational Study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.812238","article-title":"Abatacept Induces Clinical Improvement in Patients With Severe Systemic Sclerosis","volume":"43","author":"de Paoli","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"eaay4799","DOI":"10.1126\/scitranslmed.aay4799","article-title":"ICOSL+ Plasmacytoid Dendritic Cells as Inducer of Graft-Versus-Host Disease, Responsive to a Dual ICOS\/CD28 Antagonist","volume":"12","author":"Adom","year":"2020","journal-title":"Sci Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00997","article-title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation","volume":"8","author":"Maumus","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102660","article-title":"Mesenchymal Stromal Cells-Derived Extracellular Vesicles Alleviate Systemic Sclerosis Via miR-29a-3p","volume":"121","author":"Rozier","year":"2021","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136837","article-title":"Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis","volume":"22","author":"Rozier","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.770419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T08:21:07Z","timestamp":1632990067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.770419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2021.770419"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.770419","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"article-number":"770419"}}